BioDelivery Sciences International, Inc. (BDSI) financial statements (2020 and earlier)

Company profile

Business Address 4131 PARKLAKE AVENUE
RALEIGH, NC 27612
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments64442132847023
Cash and cash equivalents64442132847023
Receivables391494233
Inventory, net of allowances, customer advances and progress billings1156332
Inventory1156332 
Other undisclosed current assets4344431
Total current assets:118664043937827
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment2344440
Intangible assets, net (including goodwill)3345678
Goodwill3333333
Intangible assets, net (excluding goodwill)0112345
Other noncurrent assets     00
Other undisclosed noncurrent assets603641   3
Total noncurrent assets:6542489101111
TOTAL ASSETS:18310988521038938
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:54222618201410
Accounts payable12312910  
Accrued liabilities30137530 
Employee-related liabilities64322  
Other undisclosed accounts payable and accrued liabilities624241410
Debt    787
Derivative instruments and hedges, liabilities      4
Deferred revenue and credits 2273
Total current liabilities:54222620282925
Noncurrent Liabilities
Long-term debt and lease obligation5952482922412
Long-term debt, excluding current maturities5952482922412
Liabilities, other than long-term debt165212122
Deferred revenue and credits 202011
Other liabilities1651111
Total noncurrent liabilities:5957535043614
Total liabilities:113797970713539
Stockholders' equity
Stockholders' equity attributable to parent70309(18)3254(1)
Preferred stock0000000
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital436381314293275260151
Accumulated deficit(367)(351)(305)(310)(243)(206)(151)
Total stockholders' equity:70309(18)3254(1)
TOTAL LIABILITIES AND EQUITY:18310988521038938

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues111566216483911
Revenue, net611447269
Cost of revenue(22)(16)(19)(11)(8)(5)(2)
Cost of goods and services sold(22)(16)(0)(0)(0)(0) 
Gross profit:904042440349
Operating expenses(86)(64)(72)(68)(75)(73)(66)
Operating income (loss):4(24)(29)(64)(35)(39)(56)
Nonoperating income (expense)0(0)2700(15)(1)
Investment income, nonoperating  27    
Other nonoperating income (expense)0(0)(0)00(0)(0)
Interest and debt expense(19)(10)(9)(3)(3)  
Loss from continuing operations before income taxes:(15)(34)(11)(67)(38)(54)(57)
Income tax expense (benefit)(0)(0)16    
Net income (loss) attributable to parent:(15)(34)5(67)(38)(54)(57)
Preferred stock dividends and other adjustments (13)     
Net income (loss) available to common stockholders, diluted:(15)(46)5(67)(38)(54)(57)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(15)(34)5(67)(38)(54)(57)
Comprehensive income (loss), net of tax, attributable to parent:(15)(34)5(67)(38)(54)(57)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: